Does an Enlarged Prostate Affect Ejaculation?

An enlarged prostate can and frequently does affect ejaculation, even before any treatment begins. Roughly half of men with lower urinary tract symptoms tied to benign prostatic hyperplasia (BPH) report some form of ejaculatory change, from reduced semen volume to painful climax to the sensation that nothing comes out at all. The medications and surgeries used to treat BPH add their own layer of ejaculatory disruption, and sorting out what the disease itself does from what the treatment does is one of the trickier conversations in urology.

The Prostate’s Role in Ejaculation

The prostate sits just below the bladder and wraps around the urethra. During ejaculation, it contributes a significant portion of the fluid that makes up semen. Prostatic fluid is rich in zinc, citrate, and enzymes that help sperm function properly, and the gland’s muscular contractions help propel semen forward through the urethra.¹ When the prostate enlarges, it can squeeze the urethra, distort the anatomy around the ejaculatory ducts, and interfere with the coordinated muscle contractions that push semen outward. The region around the verumontanum, a small landmark on the urethral floor where the ejaculatory ducts open, is now understood to be a key control point for normal antegrade (forward) ejaculation.² Enlargement that distorts this zone can impair the process even without surgery or drugs in the picture.

How Common Are Ejaculatory Problems from BPH Alone

Many men assume that ejaculatory problems only show up after they start treatment for an enlarged prostate. The data say otherwise. In a comprehensive review pooling multiple studies, about 46% of men presenting with BPH-related urinary symptoms reported some form of ejaculatory dysfunction, most commonly reduced semen volume. Only about 5% had a complete absence of ejaculate; the rest noticed the volume was noticeably lower than it used to be.³

Two factors drive those numbers up substantially. The first is age: about 30% of men aged 50 to 59 reported ejaculatory dysfunction, climbing to roughly 55% in the 60 to 69 group and nearly 75% among men 70 to 80.³ The second is the severity of urinary symptoms. Men with mild lower urinary tract symptoms had about a 42% rate of ejaculatory issues, while those with severe symptoms reached 76%.³ Large-scale studies consistently confirm this strong link between worsening urinary symptoms and both erectile and ejaculatory dysfunction.⁴

One detail worth noting: although the bother men feel about ejaculatory changes didn’t correlate with age, it did correlate with how severe their urinary symptoms were. A 55-year-old with a weak stream, frequent nighttime trips to the bathroom, and reduced ejaculate volume tends to be more distressed than an otherwise healthy 70-year-old experiencing the same ejaculatory change without much urinary bother.

What the Changes Actually Feel Like

Ejaculatory dysfunction from BPH isn’t one single problem. It shows up in several ways, and men often experience more than one at the same time.

Reduced volume: The most common complaint. The amount of semen at climax is noticeably less than it used to be. This can happen because prostatic fluid production drops, the ducts are partially obstructed, or some of the ejaculate travels backward into the bladder.
Weakened force: Semen dribbles rather than being expelled forcefully. Men sometimes describe this as “losing the push.”
Painful ejaculation: In a study of nearly 3,700 sexually active men with BPH, about 19% reported pain or discomfort during ejaculation, and almost 9 out of 10 of those men said it was a real problem for them. Men with painful ejaculation also had more severe urinary symptoms overall and were more likely to report erectile difficulties and reduced ejaculate.⁵
Retrograde ejaculation: Semen goes backward into the bladder instead of out through the penis. The orgasm still happens, but little or nothing comes out. This can occur when the bladder neck, which normally clamps shut during ejaculation, doesn’t close properly because of the enlarged prostate or overactive bladder contractions in the area.

Painful ejaculation in particular tends to cluster with other sexual and urinary symptoms. Among men who reported it, 72% also had erectile dysfunction and 75% had reduced ejaculate volume.⁵ Prostatitis, which involves inflammation and pain in the prostate independent of enlargement, can compound these problems further.⁶

How BPH Medications Affect Ejaculation

If BPH itself causes ejaculatory changes, the two main drug classes used to treat it can make things more complicated. This is where men often feel caught in a bind: the medication that helps them urinate can make their ejaculation worse.

Alpha-Blockers

Alpha-blockers relax the smooth muscle in the prostate and bladder neck to improve urine flow. But that same relaxation can interfere with the muscular contractions that push semen forward. Not all alpha-blockers are equal here. In a controlled study of healthy volunteers, tamsulosin at 0.8 mg daily caused decreased ejaculate volume in almost 90% of subjects, with about 35% experiencing complete absence of ejaculate. Neither alfuzosin nor placebo produced those effects.⁷ The researchers noted that the ejaculatory problems with tamsulosin weren’t attributable to retrograde ejaculation; the semen volume simply dropped rather than being redirected into the bladder. The mechanism seems to involve suppression of the emission phase itself, where the seminal vesicles and prostate normally contract to deliver fluid into the urethra.⁸

Silodosin, another alpha-blocker that is highly selective for the prostate, has even higher rates of ejaculatory disturbance. In one study looking at men receiving silodosin alongside pelvic floor muscle training, about 7% developed ejaculatory disorders, though rates were similar whether or not the training was added.⁹ Other studies report much higher rates with silodosin. If preserving ejaculation is a priority, your urologist may steer toward alfuzosin or another less-selective alpha-blocker, though those come with their own tradeoffs in terms of blood pressure effects.

5-Alpha Reductase Inhibitors

Finasteride and dutasteride work differently from alpha-blockers. They shrink the prostate over time by blocking the conversion of testosterone into its more potent form. Their impact on ejaculation is subtler but still measurable. In a year-long study of healthy men, dutasteride reduced semen volume by about 30%, while finasteride reduced it by roughly 15%.¹⁰ At the lower dose of finasteride typically used for hair loss (1 mg daily rather than the 5 mg used for BPH), the effect on ejaculate volume was not significantly different from placebo.¹¹

At the higher BPH doses, dutasteride also reduced sperm count and motility by about 23% and 18%, respectively, after a year. Most semen parameters returned to normal ranges within about six months of stopping the drug, though sperm count in the dutasteride group remained roughly 23% below baseline even at that point.¹² For men still interested in fathering children, this recovery timeline matters, and it’s a conversation worth having before starting treatment.

Traditional Surgery and Retrograde Ejaculation

Transurethral resection of the prostate, commonly called TURP, has been the gold-standard surgical treatment for BPH for decades. It effectively carves out obstructing prostate tissue to restore urinary flow. The tradeoff is well established: ejaculatory function takes a significant hit. In one prospective study, ejaculatory function scores worsened considerably after TURP, and the loss was associated with real bother for patients, even though erection quality and ejaculatory pain were unaffected or slightly improved.¹³ A retrospective study of 264 patients found retrograde ejaculation in about 48% of sexually active men after TURP.¹⁴

The reason TURP so reliably disrupts forward ejaculation comes down to what happens near the verumontanum and bladder neck. Standard TURP removes tissue in a way that can damage the ejaculatory ducts and destroy the muscular structures that close off the bladder neck during climax. Without that closure, semen takes the path of least resistance, flowing into the bladder instead of out through the urethra. TURP can also reduce seminal fluid production by obstructing the ejaculatory ducts and preventing seminal vesicle fluid from reaching the urethra.¹⁵

Modified and Minimally Invasive Approaches

The high rate of ejaculatory dysfunction after standard TURP has driven the development of modified surgical techniques and newer minimally invasive options designed to preserve sexual function. The results have been encouraging, though no approach is perfect.

Modified TURP techniques that spare the tissue above the verumontanum (sometimes called supramontanal-sparing or ejaculation-preserving TURP) have shown striking results. One study found that 83% of patients who underwent this modified approach maintained normal ejaculation after surgery, compared with only 19% of those who had traditional TURP.¹⁶ A meta-analysis confirmed that the supramontanal-sparing approach preserved about 1 ml more semen volume compared to standard TURP.¹⁵

Among the newer minimally invasive therapies, several names keep coming up. Prostatic urethral lift (marketed as UroLift) uses small implants to hold prostate tissue apart without removing any of it. Water vapor thermal therapy (Rezūm) uses steam to destroy excess tissue in a targeted way. Aquablation uses a high-pressure water jet guided by ultrasound imaging. Prostatic artery embolization (PAE) blocks blood flow to the prostate to shrink it. All of these techniques share a key design philosophy: they avoid destroying the midline prostatic structures near the verumontanum, which is the zone most critical for maintaining forward ejaculation.¹⁷

A review comparing these options found that iTind, Rezūm, UroLift, Aquablation, and transperineal laser ablation appeared broadly comparable in their ability to spare ejaculation.¹⁸ A study comparing Aquablation, Rezūm, and a modified robotic simple prostatectomy found no significant differences in ejaculation preservation rates, urinary symptom improvement, or complication rates among the three.¹⁹

A particularly dramatic comparison came from a randomized trial of high-frequency irreversible electroporation (H-FIRE), an energy-based technique that destroys prostate cells while preserving surrounding structures. Zero patients in the H-FIRE group developed retrograde ejaculation, compared with about 54% of those who had traditional TURP.²⁰ That trial is still relatively new, and long-term follow-up data will matter, but it illustrates how rapidly the field is evolving.

Orgasm Is Not the Same as Ejaculation

Men often conflate orgasm and ejaculation, and for good reason: in normal experience, they happen simultaneously. But they are actually separate processes controlled by different nerve pathways. Orgasm is the sensation of climax, while ejaculation is the physical expulsion of semen. This distinction becomes important after prostate treatment, because a man can still have an orgasm with retrograde ejaculation or even with no ejaculate at all. The orgasm may feel different, but it doesn’t disappear.

That said, the experience isn’t always preserved cleanly. In a study of men who underwent various surgical BPH treatments, orgasm function remained stable in about a third, improved in 30%, and got worse in 36%.²¹ The men most likely to experience worse orgasms after surgery were those who had the strongest ejaculatory force before the procedure and the highest orgasm satisfaction scores going in. In other words, men who had the most to lose tended to notice the change more. Men whose ejaculation was already diminished before surgery were less likely to report a worsening in orgasmic quality.

Clinically, this means that discussing ejaculatory expectations before treatment matters. A man who still has strong, satisfying ejaculation before surgery faces a real risk of feeling a meaningful difference afterward, even with minimally invasive approaches. Conversely, a man whose ejaculation has already been declining for years may find that the improved urinary function after treatment is well worth whatever additional ejaculatory change occurs.

Overactive Bladder and the Retrograde Connection

BPH and overactive bladder frequently coexist, and the overlap complicates the ejaculatory picture. Overactive bladder involves involuntary bladder contractions, and when those contractions happen during ejaculation, they can contribute to semen being pushed backward. A study of 120 patients with retrograde ejaculation found that those who also had overactive bladder symptoms showed improvement in both sperm count and ejaculate volume after three months of treatment with an anticholinergic medication (trospium), while a control group without retrograde ejaculation saw no change.²² This suggests that for some men, what looks like a purely prostate-driven ejaculatory problem actually has a bladder component that can be addressed separately.

This is relevant because many men with an enlarged prostate also take medications for overactive bladder, and those medications may have their own effects on ejaculation. The interplay between alpha-blockers, anticholinergics, and the prostate’s own mechanical obstruction can create a situation where pinpointing the single cause of ejaculatory dysfunction is nearly impossible. Urologists increasingly treat the whole picture rather than chasing one culprit at a time.

When Fertility Is a Concern

Most men dealing with BPH are past their reproductive years, but not all. Men in their late 40s and 50s who are still considering children face a more complicated set of decisions. BPH itself reduces semen volume, medications like dutasteride can lower sperm counts by about a quarter for as long as you take them, and surgical options carry the risk of retrograde ejaculation that would make natural conception difficult or impossible.

For these men, the choice of treatment matters a great deal. Alpha-blockers like alfuzosin, which have less impact on ejaculation than tamsulosin or silodosin, may be preferred as a first step. If surgery becomes necessary, minimally invasive techniques that preserve the ejaculatory structures offer a better chance of maintaining fertility. Sperm banking before any procedure is a reasonable precaution that urologists sometimes mention but patients don’t always think to ask about. And for men already on 5-alpha reductase inhibitors, the evidence suggests that most semen parameters recover within six months of stopping the drug, though sperm count can remain modestly depressed for longer.¹²

The Anatomy That Matters Most

Recent research has shifted the understanding of which anatomical structures actually control forward ejaculation. For years, the bladder neck was considered the primary gatekeeper: if it closed properly, semen went forward; if it didn’t, semen went backward. Newer work suggests the bladder neck plays a secondary role at best. The region around the verumontanum, the prostatic apex, and a structure sometimes called the “ejaculatory hood” appear to be the real functional center of ejaculatory control.²

This updated understanding explains why techniques that spare the tissue around the verumontanum are so much better at preserving ejaculation than traditional TURP, which resects tissue across the entire prostatic urethra. It also explains a puzzle that bothered urologists for years: some men with clearly incompetent bladder necks after surgery still ejaculated forward, while others with apparently intact bladder necks developed retrograde ejaculation. The answer seems to be that the apical and midprostatic structures were doing most of the work all along. As surgical techniques continue to refine around this insight, the odds of preserving ejaculation through prostate treatment should continue to improve.